<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02191462</url>
  </required_header>
  <id_info>
    <org_study_id>14NBHC</org_study_id>
    <nct_id>NCT02191462</nct_id>
  </id_info>
  <brief_title>A Study of the Pharmacokinetics of Three Dosages of Niagen in Healthy Subjects</brief_title>
  <acronym>14NBHC</acronym>
  <official_title>A Randomized, Double-blind, Cross-over Study of the Pharmacokinetics of Three Dosages of Niagen in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KGK Synergize Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ChromaDex, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>KGK Synergize Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study in to analyse the way in which the body processes Niagen
      (nicotinamide riboside) in healthy people. Blood and urine samples from subjects who are
      given a dose of Niagen will be analyzed for metabolites over the 24 hours after taking the
      dose.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>t1/2 (terminal half-life)</measure>
    <time_frame>24 hours</time_frame>
    <description>24 hour dosing period; 3 dosing periods each separated by 7 day washout</description>
  </primary_outcome>
  <other_outcome>
    <measure>Area under the curve (AUC(0-24h)</measure>
    <time_frame>24 hours</time_frame>
    <description>24 hour dosing period; 3 dosing periods each separated by 7 day washout</description>
  </other_outcome>
  <other_outcome>
    <measure>AUCI (AUC to infinity)</measure>
    <time_frame>24 hours</time_frame>
    <description>24 hour dosing period; 3 dosing periods each separated by 7 day washout</description>
  </other_outcome>
  <other_outcome>
    <measure>AUC(0-24h)/AUCI</measure>
    <time_frame>24 hours</time_frame>
    <description>24 hour dosing period; 3 dosing periods each separated by 7 day washout</description>
  </other_outcome>
  <other_outcome>
    <measure>Maximum observed concentration (Cmax)</measure>
    <time_frame>24 hours</time_frame>
    <description>24 hour dosing period; 3 dosing periods each separated by 7 day washout</description>
  </other_outcome>
  <other_outcome>
    <measure>Time of maximum concentration (Tmax),</measure>
    <time_frame>24 hours</time_frame>
    <description>24 hour dosing period; 3 dosing periods each separated by 7 day washout</description>
  </other_outcome>
  <other_outcome>
    <measure>λ (terminal disposition rate constant)</measure>
    <time_frame>24 hours</time_frame>
    <description>24 hour dosing period; 3 dosing periods each separated by 7 day washout</description>
  </other_outcome>
  <other_outcome>
    <measure>AUCReftmax (Area under the curve to tmax)</measure>
    <time_frame>24 hours</time_frame>
    <description>24 hour dosing period; 3 dosing periods each separated by 7 day washout</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood Safety parameters</measure>
    <time_frame>24 hour dosing period; pre dose and 24 hr post dose</time_frame>
    <description>CBC</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood Safety parameters</measure>
    <time_frame>24 hour dosing period; pre dose and 24 hr post dose</time_frame>
    <description>electrolytes</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood Safety parameters</measure>
    <time_frame>24 hour dosing period; pre dose and 24 hr post dose</time_frame>
    <description>glucose</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood Safety parameters</measure>
    <time_frame>24 hour dosing period; pre dose and 24 hr post dose</time_frame>
    <description>creatinine</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood Safety parameters</measure>
    <time_frame>24 hour dosing period; pre dose and 24 hr post dose</time_frame>
    <description>AST</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood Safety parameters</measure>
    <time_frame>24 hour dosing period; pre dose and 24 hr post dose</time_frame>
    <description>ALT</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood Safety parameters</measure>
    <time_frame>24 hour dosing period; pre dose and 24 hr post dose</time_frame>
    <description>GGT</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood Safety parameters</measure>
    <time_frame>24 hour dosing period; pre dose and 24 hr post dose</time_frame>
    <description>uric acid</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood Safety parameters</measure>
    <time_frame>24 hour dosing period; pre dose and 24 hr post dose</time_frame>
    <description>bilirubin</description>
  </other_outcome>
  <other_outcome>
    <measure>Vital Signs</measure>
    <time_frame>24 hour period: pre-dose, 1h, 4h, 6h, 12h, 24h post-dose</time_frame>
    <description>Heart Rate</description>
  </other_outcome>
  <other_outcome>
    <measure>Vital Signs</measure>
    <time_frame>24 hour period: pre-dose, 1h, 4h, 6h, 12h, 24h post-dose</time_frame>
    <description>Blood Pressure</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Niagen 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 Niagen capsule (1 x 100 mg capsule) and 9 Placebo capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Niagen 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 Niagen capsules (3 x 100mg capsule) and 7 Placebo capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1000mg Niagen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 Niagen capsules (10 x 100mg capsule)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Niagen 100mg</intervention_name>
    <arm_group_label>Niagen 100mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Niagen 300mg</intervention_name>
    <arm_group_label>Niagen 300mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Niagen 1000mg</intervention_name>
    <arm_group_label>1000mg Niagen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Male or female age 30-55 years

          -  BMI 18.5-29.9 kg/m2

          -  If female, subject is not of child bearing potential, OR Females of childbearing
             potential must agree to use a medically approved method of birth control and have a
             negative urine pregnancy test result.

          -  Healthy as determined by laboratory results and medical history

          -  Agrees to maintain current level of physical activity throughout the study

          -  Agrees to avoid vitamins and St. John's Wort for 30 days prior to enrollment and
             during the study

          -  Agrees to avoid nutritional yeast, whey proteins, energy drinks, dairy products,
             grapefruit and grapefruit juice and alcohol 7 days prior to enrollment and during
             study

          -  Has given voluntary, written, informed consent to participate in the study

        Exclusion Criteria:

          -  Women who are pregnant, breastfeeding, or planning to become pregnant during the
             course of the trial.

          -  Use of natural health products (NHPs)/dietary supplements within 7 days prior to
             randomization and during the course of the study.

          -  Use of vitamins or St. John's Wort in the last 30 days before the study enrollment,

          -  Use of natural health products containing Nicotinamide riboside within 7 days prior to
             randomization and during the course of the study

          -  Use of nutritional yeast, whey proteins, energy drinks, grapefruit and grapefruit
             juice, dairy products, alcohol for 7 days prior to the study

          -  Subjects who are smokers

          -  Subjects with blood pressure ≥140/90

          -  Use of blood pressure medications

          -  Use of cholesterol lowering medications

          -  Metabolic diseases or chronic diseases

          -  Use of acute over the counter medication within 72 hours of test product dosing

          -  Unstable medical conditions as determined by the Qualified Investigator

          -  Immunocompromised individuals such as subjects that have undergone organ
             transplantation or subjects diagnosed with human immunodeficiency virus (HIV)

          -  Clinically significant abnormal lab results at screening (e.g. AST and/or ALT &gt; 2 x
             ULN, and/or bilirubin &gt; 2 x ULN) will be assessed by the Medical Investigator

          -  Subjects who have planned surgery during the course of the trial

          -  History of or current diagnosis of any cancer (except for successfully treated basal
             cell carcinoma) diagnosed less than 5 years prior to screening. Subjects with cancer
             in full remission more than 5 years after diagnosis are acceptable

          -  History of blood/bleeding disorders

          -  Blood donation in the past 2 months

          -  Alcohol abuse (&gt;2 standard alcoholic drinks per day) or drug abuse within the past 6
             months

          -  Participation in a clinical research trial within 30 days prior to randomization

          -  Allergy or sensitivity to study supplement ingredients or to any food or beverage
             provided during the study

          -  Individuals who are cognitively impaired and/or who are unable to give informed
             consent.

          -  Any other condition which in the Investigator's opinion may adversely affect the
             subject's ability to complete the study or its measures or which may pose significant
             risk to the subject
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dale Wilson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KGK Synergize Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>KGK Synergize Inc.</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2014</study_first_submitted>
  <study_first_submitted_qc>July 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2014</study_first_posted>
  <last_update_submitted>September 8, 2014</last_update_submitted>
  <last_update_submitted_qc>September 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Niagen</keyword>
  <keyword>Nicotinamide riboside</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

